Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

Abstract

Protective efficacy of novel vaccine candidates in rhesus monkeys opens new paths for the development of an HIV-1 vaccine. Despite the recent demonstration of partial HIV-1 vaccine efficacy in humans, the immune responses required to protect against acquisition of infection remain unclear. Here, Barouch et al. demonstrate vaccine protection against acquisition of a stringent strain of simian immunodeficiency virus (SIV) in rhesus monkeys. Two candidate vaccines expressing the Gag, Pol and Env viral antigens were tested. They observe a delay in acquisition of SIV in vaccinated monkeys following repeated challenges with SIVMAC251. Protection against acquisition is correlated with Env-specific antibody responses, which the authors postulate may be critical for delaying infection, although whether the antibodies are surrogates for protection or causal correlates is not yet clear. Preclinical studies of human immunodeficiency virus type 1 (HIV-1) vaccine candidates have typically shown post-infection virological control, but protection against acquisition of infection has previously only been reported against neutralization-sensitive virus challenges1,2,3. Here we demonstrate vaccine protection against acquisition of fully heterologous, neutralization-resistant simian immunodeficiency virus (SIV) challenges in rhesus monkeys. Adenovirus/poxvirus and adenovirus/adenovirus-vector-based vaccines expressing SIVSME543 Gag, Pol and Env antigens resulted in an 80% or greater reduction in the per-exposure probability of infection4,5 against repetitive, intrarectal SIVMAC251 challenges in rhesus monkeys. Protection against acquisition of infection showed distinct immunological correlates compared with post-infection virological control and required the inclusion of Env in the vaccine regimen. These data demonstrate the proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-resistant virus challenges in rhesus monkeys.